Related Experiment Video
Updated: May 22, 2025

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
Published on: April 28, 2023
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and
L Kuksa1, C Andrejak2, B Haecker3
1Riga East University Hospital, Tuberculosis and Lung Disease center, Riga, Latvia.
Abstract:
Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, "when antibiotics used for the latter form of TB do not work or cause unacceptable side effects." This restricted use implies that the older, prolonged and poorly tolerated regimens remain the recommended treatment for most cases of drug-resistant TB. The authors, representing many respiratory groups and societies, call for the label expansion of pretomanid to align with global guidelines, allowing for broader use.
More Related Videos
Related Concept Videos
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Nomenclature
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

